四、展望

在卵巢癌的治疗中,已经有多项Ⅰ/Ⅱ期研究取得一定成果，信捷职称论文写作发表网，大规模的Ⅲ期试验也正在展开，在辅助诊断及预后因子方面也有新的发现，Bunting P等发现NESI血清浓度与CA125无关，高度特异性及敏感性明显优于其他标志物，在卵巢癌的早期诊断给预后监测的方面有着广阔的前景[33，34]。西班牙Vall d Hebron大学医院Castellvi医师等的一项研究显示: p-4EBP1的表达与卵巢癌预后显著相关(P= 0.005)，且在多变量分析中与外科分期显著相关[35]。美国MD安德森癌症治疗中心的科学家先后对111个和132个卵巢癌样本进行分析。结果发现，卵巢癌患者的预期寿命与人体内的两种酶水平有直接联系，人体内两种核糖核酸酶Dicer和Drosha含量高的患者平均存活11年，而含量低的患者则平均2.66年[36]。卵巢癌的化疗耐药是临床急需解决的问题，寻求更多卵巢癌治疗的靶标及相应的靶向治疗药物对卵巢癌患者尤其重要。

【参考文献】

1 Posadas EM,Davidson B,Kohn EC,et al.Proteomics and ovarian cancer :implications for diagnosis and treatment:a critical review the recent literature[J].Curr Opin Oncol.2004,16(5):478-484.

2 McGuire WP,Hoskins WJ,Brady MF,et al.Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer.N Engl J Med,1996,334:1-6.

3 Bookman MA,Brady MF,McGuire WP,et al. Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup[J].J Clin Oncol. 2009 Feb 17.

4 van Zon A, Mossink MH, Schoester M, et al. Efflux kinstics and intracellular distribution of daunorubicin are not affected by major vault protein/lung resistance-related protein ( vault) expression[J]. Cancer Res, 2004 Jul 15;64(14):4887-92.

5 Gregoriadis G.Liposome Technology (Vol 3) [M] . Boca Raton : CRC Press , 1984 : 75～941.

6 Zhang J, Chen AP, Wang B, et al.Correlations of EGFR and LRP to chemotherapy resistance and prognosis of ovarian cancer[J].Ai Zheng.2008 Dec;27(12):1331-6.

7 Cannistra SA, Matulonis UA, Penson RT,et al.Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer[J].J Clin Oncol. 2007 Nov 20;25(33):5180-6.

8 Mabuchi S, Terai Y, Morishige K，et al. Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model[J]. Clin Cancer Res. 2008 Dec 1;14(23):7781-9.

9 Chodankar R, Kwang S, Sangiorgi F，et al.Cell-nonautonomous induction of ovarian and uterine serous cystadenomas in mice lacking a functional Brca1 in ovarian granulosa cells[J]. Curr Biol.2005 Mar 29;15(6):561-5.

10 Kauff ND.Is It time to stratify for BRCA mutation status in therapeutic trials in ovarian cancer[J]?J Clin Oncol.2008 Jan 1;26(1):9-10.

11 Yin MB, Guo B, Voigt W, et al. Novel cellular determinants for reversal of multidrug resistance in cells expressing P170-glycoprotein[ J ].Biochim Biophys Acta 1998 Mar 5;1401(3):265-76.

12 Katagiri A, Tomita Y, Nishiyama T, et al.Immunohistochemical detection of P-glycoprotein and GSTP1-1 in testis cancer[ J ]. Br J Cancer. 1993 Jul;68(1):125-9.

13 Vanhoefer U, Yin MB, Harstrick A, et al. Carbamoylation of glutathione reductase by N,N-bis(2-chloroethyl)-N- nitrosourea associated with inhibition of multidrug resistance protein (MRP) function[ J ]. Biochem Pharmacol. 1997 Mar 21;53(6):801-9.

14 Rosen LS, Laxa B, Boulos L, et al.Phase 1 study of TLK286 (Telcyta) administered weekly in advanced malignancies[J].Clin Cancer Res. 2004 Jun 1;10(11):3689-98.

15　Kavanagh JJ, Gershenson DM, Choi H,et al.Multi-institutional phase 2 study of TLK286 (TELCYTA, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer[J].Int J Gynecol Cancer. 2005 Jul-Aug;15(4):593-600.

16 Garcia AA, Hirte H, Fleming G,et al.Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia[J]. J Clin Oncol. 2008 Jan 1;26(1):76-82.

17 Azad NS, Posadas EM, Kwitkowski VE, Combination targeted therapy wi